Eurocine Vaccines is a brand that aims to develop a diverse portfolio of vaccine candidates, covering different phases of pharmaceutical product development. With expertise in preclinical and clinical studies, quality assurance, industrial manufacturing, as well as legal and commercial aspects, Eurocine Vaccines ensures that innovative vaccines have the opportunity to reach the market quickly for the benefit of humanity. By offering risk diversification to investors, the brand provides greater future leverage.

Eurocine Vaccines is currently focused on developing a therapeutic vaccine candidate against Herpes Simplex Virus type 2 (HSV-2). This vaccine addresses the need for an efficient cure for the infection, which affects nearly 500 million people worldwide. The brand is evaluating two potential technologies, protein, and mRNA, to develop the HSV-2 vaccine candidate.

Additionally, Eurocine Vaccines is considering a prophylactic vaccine candidate for HSV-2 infections based on WHO's preferred product characteristics. The brand is also working on developing a prophylactic vaccine candidate against Chlamydia trachomatis, a common sexually transmitted disease with significant health implications. The vaccine aims to prevent complications such as inflammation, pelvic pain, ectopic pregnancy, infertility, and the transmission of other sexually transmitted diseases.

By providing preventive vaccines, Eurocine Vaccines seeks to reduce the extensive use of antibiotics and combat antibiotic resistance. The brand's ultimate goal is to improve global health by developing safe and effective vaccines